Oral Psoriatic Arthritis Drug Enters Phase 2 Trial
Adults with active psoriatic arthritis may one day have an oral option, but the drug is still being tested.
Updated on Nov. 5, 2026 in Arthritis
The U.S. FDA has cleared Forward Therapeutics' investigational new drug application for a Phase 2 study of FT2109, an oral investigational drug being tested for active psoriatic arthritis. The company plans to begin the study in December 2026, and the trial will randomize about 210 adults to FT2109 or placebo.
Why it matters
Psoriatic arthritis is commonly treated with biologic TNF inhibitors given by injection or infusion, so an oral agent that targets TNF signaling would, if it proves effective and safe, offer a different route of treatment. This is an early step: clearance allows the trial to proceed but says nothing yet about whether the drug works in patients.
The Phase 1 study enrolled 90 healthy participants and reported the drug was well tolerated, with dose-proportional pharmacokinetics supporting once-daily oral dosing. Preclinical disease models showed anti-inflammatory activity comparable to biologic TNF inhibition, but no patient efficacy data exist yet.
The players
Forward Therapeutics
A Boston-based company developing FT2109, an oral selective soluble TNF signaling inhibitor for inflammatory conditions including psoriatic arthritis.
U.S. Food and Drug Administration
The federal agency that reviews and clears investigational new drug applications before human trials can begin in the United States.
The details
FT2109 is designed as an oral selective soluble TNF signaling inhibitor, aiming to dampen the inflammatory signal that TNF drives without the full blockade used by injected biologics. In preclinical studies it showed high potency and good oral absorption. The Phase 2 study, FT2109-2201, will randomize participants to FT2109 or placebo for 12 weeks alongside permitted background therapy, testing two once-daily doses.
Timeline
November 5, 2026: FDA clearance of the investigational new drug application for the Phase 2 study was announced.
December 2026: Forward Therapeutics plans to begin the Phase 2 study.
Week 12: The primary endpoint, ACR20 response, will be assessed after the 12-week treatment period.
Health Landscape
Injected biologic TNF inhibitors are a long-established option for psoriatic arthritis. FT2109 is an early-stage oral candidate that would need Phase 2 results before it could be compared with that standard of care.
For people living with psoriatic arthritis, this is an early pipeline development with no change to current care yet. Anyone considering treatment options should discuss with their rheumatologist which approved therapies fit their situation.
The takeaway
Clearance to begin a Phase 2 trial is an important step, but it is not proof of benefit. Readers with psoriatic arthritis should keep following results and talk with their physician about currently approved options.
What happens next
Forward Therapeutics plans to start the Phase 2 study in December 2026, and the primary endpoint results will follow after the 12-week treatment period.
Further reading
Explore more on Arthritis treatment research and how new therapies are developed.
Source note: This article includes information reported by The Manila times.
